Protalix BioTherapeutics (NYSE:PLX - Get Free Report) was downgraded by research analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued on Thursday.
Separately, HC Wainwright lifted their target price on Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a "buy" rating in a report on Monday, February 3rd.
Check Out Our Latest Report on Protalix BioTherapeutics
Protalix BioTherapeutics Trading Up 5.5 %
Shares of PLX traded up $0.13 during trading hours on Thursday, reaching $2.49. 678,007 shares of the company's stock traded hands, compared to its average volume of 433,399. Protalix BioTherapeutics has a 12 month low of $0.82 and a 12 month high of $2.76. The stock has a market cap of $194.30 million, a PE ratio of -19.15 and a beta of 0.72. The firm's 50 day simple moving average is $2.40 and its 200-day simple moving average is $1.76.
Institutional Investors Weigh In On Protalix BioTherapeutics
Several large investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC grew its stake in shares of Protalix BioTherapeutics by 24.1% in the 4th quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company's stock worth $55,000 after buying an additional 5,686 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its holdings in shares of Protalix BioTherapeutics by 13.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 53,507 shares of the company's stock valued at $101,000 after acquiring an additional 6,434 shares during the last quarter. Millennium Management LLC grew its position in Protalix BioTherapeutics by 3.8% in the fourth quarter. Millennium Management LLC now owns 387,921 shares of the company's stock worth $729,000 after acquiring an additional 14,164 shares in the last quarter. Squarepoint Ops LLC increased its stake in Protalix BioTherapeutics by 33.4% during the fourth quarter. Squarepoint Ops LLC now owns 73,940 shares of the company's stock worth $139,000 after acquiring an additional 18,522 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Protalix BioTherapeutics during the fourth quarter valued at approximately $35,000. 16.53% of the stock is owned by institutional investors.
Protalix BioTherapeutics Company Profile
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
See Also
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
